Want to see TSE:RX full AI Analyst Report?
RX Stock Chart & Stats
C$15.70
-C$0.09(-0.61%)
At close: 4:00 PM EDT
C$15.70
-C$0.09(-0.61%)
Day’s Range― - ―
52-Week RangeC$10.65 - C$16.25
Previous CloseN/A
Volume2.74K
Average Volume (3M)14.13K
Market Cap
C$180.60M
Enterprise ValueC$162.82
Total Cash (Recent Filing)C$8.94M
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)18.1
Beta0.84
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.35%
Share Statistics
EPS (TTM)0.88
Shares Outstanding11,308,835
10 Day Avg. Volume10,542
30 Day Avg. Volume14,130
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.00Price Target Upside14.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)C$69.00M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthBiosyent is expanding its marketed-product base and commercial reach, with multi-year revenue growth providing a durable foundation for earnings. Continued product adoption and portfolio development could support further sales growth.
High ProfitabilityHigh gross, operating, and net margins indicate strong economics in Biosyent’s specialty-pharmaceutical commercialization model. These margins provide capacity to fund marketing, regulatory support, and portfolio expansion while retaining substantial earnings.
Conservative Balance SheetVery low leverage and growing equity give Biosyent financial flexibility to withstand operating variability and pursue licensing or acquisition opportunities. The conservative balance sheet also limits interest burden and supports resilience across business cycles.
Bears Say
Margin CompressionAlthough profitability remains strong, declining margins versus prior years suggest product-mix changes or rising costs as the portfolio scales. If this persists, incremental revenue may translate into slower earnings growth and reduce the benefit of operating leverage.
Variable Cash ConversionCash generation is healthy but less consistent than reported earnings, with recent free-cash-flow decline and operating cash flow below net income. Working-capital movements or reinvestment needs could constrain internally funded expansion if variability continues.
Rising Debt, Despite Low LeverageCurrent leverage is very conservative, but the increase in debt introduces a developing balance-sheet watch point. Borrowing that grows faster than revenue or cash generation could gradually reduce financial flexibility and increase exposure to funding costs.
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$10.65 and its highest was C$16.25 in the past 12 months.
What is Biosyent Inc’s market cap?
Biosyent Inc’s market cap is C$180.60M.
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is Nov 12, 2026 which is in 66 days.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on Aug 20, 2026. The company reported C$0.25 earnings per share for the quarter.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.055 which represents an annual dividend yield of 1.35%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,308,835 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.25 in its last earnings report. Following the earnings report the stock price went up 4.217%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biosyent Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$18.00 (14.65% Upside)
C$18.00 (14.65% Upside)
Insider Transactions
Sold Shares
Worth C$402.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.73%
12-Months-Change
Fundamentals
Return on Equity
1.35%
Trailing 12-Months
Asset Growth
39.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biosyent Inc
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
RX Stock 12 Month Forecast
Average Price Target
C$18.00
▲(14.65% Upside)
Technical Analysis
Aequus Pharmaceuticals
―
Willow Biosciences Inc
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―